Our group has previously identified that activin preferentially signals along the PI3K/AKT pathway in the absence of SMAD4 while TGF-β favors the MAPK/ERK pathway in the absence of SMAD4 in CRC [8]. This evidence concerns the gene AKT1 and colorectal carcinoma.